Format

Send to

Choose Destination
J Am Coll Cardiol. 2018 Jul 10;72(2):187-198. doi: 10.1016/j.jacc.2018.04.053.

Association of IL-8 With Infarct Size and Clinical Outcomes in Patients With STEMI.

Author information

1
Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; Center for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway; Center for Heart Failure Research, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: chrshe@ous-hf.no.
2
Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; National Association for Heart and Lung Diseases Clinics, Feiring Heart Clinic, Feiring, Norway.
3
Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; Department of Cardiology, Section of Interventional Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
4
Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; Center for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway; Center for Heart Failure Research, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
5
Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital and University of Oslo, Oslo, Norway.
6
Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; Center for Heart Failure Research, Oslo, Norway.

Abstract

BACKGROUND:

Little is known about the role of interleukin (IL)-8 in patients with acute ST-segment elevation myocardial infarction (STEMI).

OBJECTIVES:

The aims of this study were to evaluate, in STEMI patients, the temporal profile of IL-8 and possible associations with left ventricular (LV) function and remodeling, infarct size, microvascular obstruction, myocardial salvage, and future clinical events.

METHODS:

A total of 258 patients with STEMI were included. Blood samples were drawn before and immediately after percutaneous coronary intervention (PCI), at day 1, and after 4 months. Cardiac magnetic resonance imaging was performed in the acute phase and after 4 months. Clinical events were registered during 12 months' follow-up and all-cause mortality after median 70 months' follow-up.

RESULTS:

Patients with IL-8 levels greater than the median measured both immediately after PCI and at day 1 had larger final infarct size, lower LV ejection fraction, larger increase in LV end-diastolic volume, and higher frequency of microvascular obstruction. After multivariate adjustment, high IL-8 levels at day 1 were associated with an increased risk of developing a large MI and having reduced LV ejection fraction at 4 months, also after adjustment for peak troponin value. Patients with IL-8 levels in the highest quartile measured at all sampling points were more likely to have a clinical event during the first 12 months after the MI and had lower overall survival during long-term follow-up.

CONCLUSIONS:

High levels of circulating IL-8 were associated with large infarct size, impaired recovery of LV function, and adverse clinical outcome in patients with STEMI, suggesting IL-8 as a future therapeutic target based on its important role in post-infarction inflammation.

KEYWORDS:

acute myocardial infarction; inflammation; interleukin-8

PMID:
29976293
DOI:
10.1016/j.jacc.2018.04.053

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center